Abbonarsi

A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia - 21/09/21

Doi : 10.1016/j.rmed.2021.106541 
Nicla Orzes a, 1, Laura Pini a, b, , 1 , Guido Levi a, Silvia Uccelli a, Francesca Cettolo a, Claudio Tantucci a, b
a Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy 
b Respiratory Medicine Unit, Spedali Civili di Brescia, Brescia, Italy 

Corresponding author. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Objective

This study investigated the consequences of Coronavirus Disease 2019 (COVID-19) pneumonia on lung function in the first 6 months after hospital discharge.

Methods

A prospective lung function assessment in SARS-CoV2 patients with COVID-19 pneumonia, hospitalized between March and April 2020, was conducted with spirometry measurements including lung volumes, mainly total lung capacity (TLC), lung diffusion capacity for carbon monoxide (DLCO) collected at 3 months after hospital discharge. Patients with restrictive ventilatory defect or impaired DLCO or both were re-evaluated at 6 months with global spirometry and chest HRCT scan.

Results

Among 40 consecutive patients, 19 (48%) had normal pulmonary functional tests (group A), and 21 (52%) showed residual lung function abnormalities at 3 months after hospital discharge (group B). In group B, 4 patients (19%) had only loss of lung volume as shown by TLC reduction (group 1), 13 patients (62%) had decreased both TLC and DLCO (group 2), and 4 patients (19%) had isolated reduction in DLCO (group 3). At 6-month follow-up in group 1, although all patients improved, only one normalized total lung capacity (TLC). In group 2, TLC and DLCO increased significantly (p < 0.01), but only 3 patients reached normal values. In group 3, DLCO improved for most patients, normalizing in 50% of them. At 6-months significant correlations between an internal-built chest HRCT scan severity score and TLC (r2 = 0.33; p < 0.01) and DLCO (r2 = 0.32; p < 0.01) were found.

Conclusions

Nearly 50% of patients recovered in the post-critical phase. Most of those with abnormal pulmonary function tests at 3 months improved subsequently, but only another 29% (6 out of 21) reached normal values at 6 months. These results indicate that lung function spontaneous recovery is faster at first and occurs more slowly thereafter, leaving more than one third (15 out of 40) of patients with abnormal lung function tests at 6 months.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

After COVID-19 pneumonia, nearly 50% of patients fully recovered lung function.
Most of those with abnormal pulmonary function tests at 3 months improved later.
However, only another 29% reached normal values at 6 months.
Lung function recovery is faster at first and occurs more slowly thereafter.
More than one-third of patients keep abnormal lung function tests at 6 months.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : COVID-19, SARS-CoV2, Lung function, Pneumonia, Spirometry


Mappa


© 2021  Elsevier Ltd. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 186

Articolo 106541- settembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease
  • Masato Kono, Koichi Miyashita, Ryutaro Hirama, Yuiko Oshima, Kenichiro Takeda, Yasutaka Mochizuka, Akari Tsutsumi, Hideki Miwa, Yoshihiro Miki, Dai Hashimoto, Takafumi Suda, Hidenori Nakamura
| Articolo seguente Articolo seguente
  • Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis
  • Jesus Sancho, Santos Ferrer, Enric Burés, José Luis Díaz, Teresa Torrecilla, Jaime Signes-Costa, Emilio Servera

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.